tiprankstipranks
Trending News
More News >
RaQualia Pharma Inc. (JP:4579)
:4579
Japanese Market
Advertisement

RaQualia Pharma Inc. (4579) AI Stock Analysis

Compare
1 Followers

Top Page

JP:4579

RaQualia Pharma Inc.

(4579)

Rating:54Neutral
Price Target:
¥540.00
▲(3.45%Upside)
RaQualia Pharma Inc. has a moderate score driven by strong cash flow management and a stable balance sheet. However, the stock's valuation is concerning due to negative earnings, and technical indicators suggest short-term bearish momentum. Investors should be cautious and focus on the company's ability to improve its profitability metrics.

RaQualia Pharma Inc. (4579) vs. iShares MSCI Japan ETF (EWJ)

RaQualia Pharma Inc. Business Overview & Revenue Model

Company DescriptionRaQualia Pharma Inc. is a Japan-based pharmaceutical company engaged in the research, development, and commercialization of innovative pharmaceutical products. The company focuses on creating novel drugs primarily within the therapeutic areas of pain management, gastrointestinal disorders, and oncology. Through its dedication to advancing healthcare solutions, RaQualia Pharma strives to address unmet medical needs and improve patient outcomes.
How the Company Makes MoneyRaQualia Pharma Inc. generates revenue through the development and commercialization of pharmaceutical products. The company primarily earns money by out-licensing its proprietary drug candidates to larger pharmaceutical companies that have the resources to conduct late-stage clinical trials and bring the products to market. These licensing agreements typically involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on sales once the products are commercialized. Additionally, the company may engage in collaborative research and development partnerships, which can provide financial support and shared expertise, further contributing to its revenue streams.

RaQualia Pharma Inc. Financial Statement Overview

Summary
RaQualia Pharma Inc. exhibits potential in financial health with strong cash flow management and a stable balance sheet. However, the company struggles with consistent profitability and revenue growth. The gross profit margin is robust, but operational losses need to be addressed to improve net profitability.
Income Statement
58
Neutral
RaQualia Pharma Inc. has shown a volatile revenue growth pattern with recent TTM revenue increasing by 10.19% from the previous annual report, but with a declining trend compared to earlier years. The company struggles with profitability as indicated by negative net profit margins and EBIT margins in the recent periods, primarily due to consistent net losses. While gross profit margins remain strong at around 74.96% in TTM, the company needs to focus on reducing operational losses to improve overall profitability.
Balance Sheet
65
Positive
The balance sheet reveals a moderate financial structure with a debt-to-equity ratio of 0.61 in TTM, indicating manageable leverage. The equity ratio remains robust at 57.82%, reflecting a solid equity base relative to total assets. However, the recent reduction in stockholders' equity highlights potential risks. Despite these concerns, the company maintains healthy liquidity with substantial cash reserves, suggesting resilience against short-term financial stress.
Cash Flow
70
Positive
Cash flow analysis shows a promising trend with a strong operating cash flow to net income ratio of -0.69 in TTM, highlighting efficient cash generation relative to reported losses. The free cash flow has improved significantly, growing by 131.36% from the last annual report, indicating better cash management. However, the company needs to ensure sustainable operating cash flows to support long-term growth.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.11B1.90B2.92B2.78B1.11B
Gross Profit2.48B1.66B2.69B2.46B969.29M
EBITDA188.27M-111.80M1.00B1.02B-403.25M
Net Income-495.03M-323.66M723.39M755.79M-606.99M
Balance Sheet
Total Assets9.66B6.87B6.26B5.23B4.25B
Cash, Cash Equivalents and Short-Term Investments3.34B3.76B3.93B2.66B2.11B
Total Debt3.45B367.72M222.34M39.07M45.52M
Total Liabilities4.08B752.00M760.67M446.19M240.11M
Stockholders Equity5.57B6.12B5.50B4.79B4.01B
Cash Flow
Free Cash Flow84.24M-940.80M1.45B260.61M-445.56M
Operating Cash Flow180.94M-718.60M1.48B366.03M-289.21M
Investing Cash Flow-3.67B-135.37M-47.65M-279.25M225.47M
Financing Cash Flow2.98B793.45M-29.56M-16.44M-6.96M

RaQualia Pharma Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price522.00
Price Trends
50DMA
570.66
Negative
100DMA
480.22
Positive
200DMA
455.15
Positive
Market Momentum
MACD
-7.59
Negative
RSI
42.83
Neutral
STOCH
50.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4579, the sentiment is Negative. The current price of 522 is below the 20-day moving average (MA) of 528.60, below the 50-day MA of 570.66, and above the 200-day MA of 455.15, indicating a neutral trend. The MACD of -7.59 indicates Negative momentum. The RSI at 42.83 is Neutral, neither overbought nor oversold. The STOCH value of 50.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4579.

RaQualia Pharma Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
¥13.75B284.55
0.73%-13.57%-106.11%
55
Neutral
¥13.82B
256.62%81.71%
54
Neutral
¥12.94B
57.13%-66.39%
49
Neutral
¥21.32B205.45
8.46%49.97%
47
Neutral
¥19.20B
-100.00%-1079.89%
46
Neutral
C$202.78M-3.27-23.14%2.83%20.78%-1.17%
44
Neutral
¥14.68B
11.93%15.04%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4579
RaQualia Pharma Inc.
522.00
-138.00
-20.91%
JP:4588
Oncolys BioPharma, Inc.
583.00
-1.00
-0.17%
JP:4599
StemRIM Inc.
307.00
-142.00
-31.63%
JP:4880
CellSource Co., Ltd.
689.00
-861.45
-55.56%
JP:4888
STELLA PHARMA CORPORATION
434.00
-17.00
-3.77%
JP:4978
ReproCELL Inc.
214.00
77.00
56.20%

RaQualia Pharma Inc. Corporate Events

RaQualia Pharma Reports Strong Sales Growth Amid Profitability Challenges
May 15, 2025

RaQualia Pharma Inc. reported a significant increase in net sales and operating profit for the first quarter of 2025, with net sales rising by 48.8% compared to the previous year. Despite the positive sales growth, the company recorded a slight loss attributable to the owners of the parent, indicating ongoing challenges in achieving profitability. The financial results reflect the company’s strategic focus on expanding its market presence and improving operational efficiencies, although it continues to face hurdles in translating sales growth into net profit.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 30, 2025